Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | CCR5 | P51681 | 2/20 | 0.34 |
| ▸ | LDHA | P00338 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.33 |
| ▸ | CTSC | P53634 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | REN | P00797 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMYD3 | Q9H7B4 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6695448 | 1.00 | DGAT1 (0.38) | DGAT1CCR5LDHATP53MDM2 | |
| SCHEMBL6695456 | 1.00 | DGAT1 (0.38) | DGAT1CCR5LDHATP53MDM2 | |
| SCHEMBL6650666 | 0.85 | TDP1 (0.43) | — | |
| SCHEMBL6650669 | 0.85 | TDP1 (0.43) | — | |
| SCHEMBL6650677 | 0.85 | TDP1 (0.43) | — | |
| SCHEMBL6655404 | 0.84 | BACE1 (0.40) | DGAT1ALDH1A1RENHPGD | |
| SCHEMBL6655395 | 0.84 | BACE1 (0.40) | DGAT1ALDH1A1RENHPGD | |
| SCHEMBL6655400 | 0.84 | BACE1 (0.40) | DGAT1ALDH1A1RENHPGD | |
| SCHEMBL5946157 | 0.79 | ALDH1A1 (0.39) | CTSCALDH1A1HPGD | |
| Hydrochloric Acid SCHEMBL5946146 | 0.78 | ALDH1A1 (0.39) | CTSCALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | AVENTIS PHARMACEUTICALS INC. (US) | 2004-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142999-A1 | Novel compounds and compositions as cathepsin inhibitors | CTSS, CTSB, CTSE | DGAT1 2695/4885CCR5 1644/4885LDHA 1954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.